155 related articles for article (PubMed ID: 33726923)
1. Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: Systematic review and meta-analysis.
Koulaouzidis G; Yung AE; Yung DE; Skonieczna-Żydecka K; Marlicz W; Koulaouzidis A; Charisopoulou D
Curr Probl Cancer; 2021 Oct; 45(5):100723. PubMed ID: 33726923
[TBL] [Abstract][Full Text] [Related]
2. Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
Staropoli N; Scionti F; Farenza V; Falcone F; Luciano F; Renne M; Di Martino MT; Ciliberto D; Tedesco L; Crispino A; Labanca C; Cucè M; Esposito S; Agapito G; Cannataro M; Tassone P; Tagliaferri P; Arbitrio M
Biomed Pharmacother; 2024 May; 174():116478. PubMed ID: 38547766
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials.
Eiger D; Franzoi MA; Pondé N; Brandão M; de Angelis C; Schmitt Nogueira M; de Hemptinne Q; de Azambuja E
ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079624
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
Minichillo S; Gallelli I; Barbieri E; Cubelli M; Rubino D; Quercia S; Dall'Olio M; Rapezzi C; Zamagni C
BMC Cancer; 2017 Nov; 17(1):722. PubMed ID: 29115937
[TBL] [Abstract][Full Text] [Related]
5. Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):250-257. PubMed ID: 31988685
[TBL] [Abstract][Full Text] [Related]
6. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.
Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M;
Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662
[TBL] [Abstract][Full Text] [Related]
7. Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Reinhorn D; Kuchuk I; Shochat T; Nisenbaum B; Sulkes A; Hendler D; Rotem O; Tsoref D; Olitzky O; Goldvaser H; Sarfaty M; Neiman V; Prus J; Gottfried M; Yust-Katz S; Yerushalmi R
Breast Cancer Res Treat; 2021 Jul; 188(2):379-387. PubMed ID: 33772709
[TBL] [Abstract][Full Text] [Related]
8. Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy.
Zhang F; Wang S; Liang S; Yu C; Li S; Chen H; Wang S; Zhu T
Cardiol Res Pract; 2021; 2021():6640673. PubMed ID: 33747560
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
10. Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Ibragimova KIE; Geurts SME; Croes S; Erdkamp F; Heijns JB; Tol J; Vriens BEPJ; Aaldering KNA; Dercksen MW; Pepels MJAE; Peters NAJB; van de Winkel L; Tilli DJP; Vriens IJH; de Boer M; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2021 Jul; 188(2):571-581. PubMed ID: 33743103
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Im YH; Karabulut B; Lee KS; Park BW; Adhav A; Cinkir HY; Abdel-Razeq H; Chang YC; Aksoy S; Im SA; Jeong J; Chae Y; Bowles J; Slimane K; Xue H; Kim SB
Breast Cancer Res Treat; 2021 Jul; 188(1):77-89. PubMed ID: 33728524
[TBL] [Abstract][Full Text] [Related]
12. Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies.
Surette A; Yoo BH; Younis T; Matheson K; Rameh T; Snowdon J; Bethune G; Rosen KV
Breast Cancer Res Treat; 2021 Jun; 187(3):743-758. PubMed ID: 33728523
[TBL] [Abstract][Full Text] [Related]
13.
Rainone P; De Palma A; Sudati F; Roffia V; Rigamonti V; Salvioni L; Colombo M; Ripamonti M; Spinelli AE; Mazza D; Mauri P; Moresco RM; Prosperi D; Belloli S
Int J Nanomedicine; 2021; 16():1943-1960. PubMed ID: 33727808
[TBL] [Abstract][Full Text] [Related]
14. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
Loibl S; Marmé F; Martin M; Untch M; Bonnefoi H; Kim SB; Bear H; McCarthy N; Melé Olivé M; Gelmon K; García-Sáenz J; Kelly CM; Reimer T; Toi M; Rugo HS; Denkert C; Gnant M; Makris A; Koehler M; Huang-Bartelett C; Lechuga Frean MJ; Colleoni M; Werutsky G; Seiler S; Burchardi N; Nekljudova V; von Minckwitz G
J Clin Oncol; 2021 May; 39(14):1518-1530. PubMed ID: 33793299
[TBL] [Abstract][Full Text] [Related]
16. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
Chang GC; Lam DC; Tsai CM; Chen YM; Shih JY; Aggarwal S; Wang S; Kim SW; Kim YC; Wahid I; Li R; Lim DW; Sriuranpong V; Chan RT; Lorence RM; Carriere P; Raabe C; Cseh A; Park K
Int J Clin Oncol; 2021 May; 26(5):841-850. PubMed ID: 33783657
[TBL] [Abstract][Full Text] [Related]
17. Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab.
De Sanctis R; Giordano L; D'Antonio F; Agostinetto E; Marinello A; Guiducci D; Masci G; Losurdo A; Zuradelli M; Torrisi R; Santoro A
Breast; 2021 Jun; 57():80-85. PubMed ID: 33780903
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes in Patients With
Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F
J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274
[TBL] [Abstract][Full Text] [Related]
19. In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties.
Nutt MJ; Yee YS; Buyan A; Andrewartha N; Corry B; Yeoh GCT; Stewart SG
Eur J Med Chem; 2021 May; 217():113353. PubMed ID: 33773263
[TBL] [Abstract][Full Text] [Related]
20. The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.
Golden E; Rashwan R; Woodward EA; Sgro A; Wang E; Sorolla A; Waryah C; Tie WJ; Cuyàs E; Ratajska M; Kardaś I; Kozlowski P; Johnstone EKM; See HB; Duffy C; Parry J; Lagerborg KA; Czapiewski P; Menendez JA; Gorczyński A; Wasag B; Pfleger KDG; Curtis C; Lee BK; Kim J; Cursons J; Pavlos NJ; Biernat W; Jain M; Woo AJ; Redfern A; Blancafort P
Nat Commun; 2021 Mar; 12(1):1920. PubMed ID: 33772001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
